| 10430536
|
Application of oral bioavailability surrogates in the design of orally active inhibitors of rhinovirus replication. |
J Pharm Sci |
1999 |
Stratford RE Jr;Clay MP;Heinz BA;Kuhfeld MT;Osborne SJ;Phillips DL;Sweetana SA;Tebbe MJ;Vasudevan V;Zornes LL;Lindstrom TD |
View
More |
| 11931615
|
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics. |
J Med Chem |
2002 |
Dragovich PS;Prins TJ;Zhou R;Brown EL;Maldonado FC;Fuhrman SA;Zalman LS;Tuntland T;Lee CA;Patick AK;Matthews DA;Hendrickson TF;Kosa MB;Liu B;Batugo MR;Gleeson JP;Sakata SK;Chen L;Guzman MC;Meador JW 3rd;Ferre RA;Worland ST |
View
More |
| 12627933
|
Pleconaril, a novel antipicornaviral agent. |
Pharmacotherapy |
2003 |
Florea NR;Maglio D;Nicolau DP |
View
More |
| 12852746
|
An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. |
J Med Chem |
2003 |
Watson KG;Brown RN;Cameron R;Chalmers DK;Hamilton S;Jin B;Krippner GY;Luttick A;McConnell DB;Reece PA;Ryan J;Stanislawski PC;Tucker SP;Wu WY;Barnard DL;Sidwell RW |
View
More |
| 14521419
|
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. |
J Med Chem |
2003 |
Dragovich PS;Prins TJ;Zhou R;Johnson TO;Hua Y;Luu HT;Sakata SK;Brown EL;Maldonado FC;Tuntland T;Lee CA;Fuhrman SA;Zalman LS;Patick AK;Matthews DA;Wu EY;Guo M;Borer BC;Nayyar NK;Moran T;Chen L;Rejto PA;Rose PW;Guzman MC;Dovalsantos EZ;Lee S;McGee K;Mohajeri M;Liese A;Tao J;Kosa MB;Liu B;Batugo MR;Gleeson JP;Wu ZP;Liu J;Meador JW 3rd;Ferre RA |
View
More |
| 14638501
|
Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. |
Antimicrob Agents Chemother |
2003 |
Hayden FG;Turner RB;Gwaltney JM;Chi-Burris K;Gersten M;Hsyu P;Patick AK;Smith GJ 3rd;Zalman LS |
View
More |
| 15105133
|
In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. |
Antimicrob Agents Chemother |
2004 |
Barnard DL;Hubbard VD;Smee DF;Sidwell RW;Watson KG;Tucker SP;Reece PA |
View
More |
| 15917520
|
In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. |
Antimicrob Agents Chemother |
2005 |
Patick AK;Brothers MA;Maldonado F;Binford S;Maldonado O;Fuhrman S;Petersen A;Smith GJ 3rd;Zalman LS;Burns-Naas LA;Tran JQ |
View
More |
| 19906491
|
Zinc lozenges as cure for the common cold--a review and hypothesis. |
Med Hypotheses |
2010 |
Eby GA 3rd |
View
More |
| 3293505
|
Antiviral chemotherapy today and tomorrow. |
Ann Med Interne (Paris) |
1988 |
De Clercq E |
View
More |
| 9397174
|
Antirhino/enteroviral vinylacetylene benzimidazoles: a study of their activity and oral plasma levels in mice. |
J Med Chem |
1997 |
Tebbe MJ;Spitzer WA;Victor F;Miller SC;Lee CC;Sattelberg TR Sr;McKinney E;Tang JC |
View
More |
